SGLT2 Inhibitors Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.
Conditions: Chronic Renal Failure; Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis Interventions: Drug: Dapagliflozin 10mg Tab; Drug: Balcinrenone 50mg Capsule; Drug: Balcinrenone 100mg Capsule; Drug: Dapagliflozin matching Placebo; Drug: Balcinrenone 50mg matching Placebo; Drug: Balcinrenone 100mg matching Placebo Sponsor: Klinikum Nürnberg Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 1, 2023 Category: Research Source Type: clinical trials

Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors
Conditions: Obesity; Weight Loss Interventions: Drug: Empagliflozin Arm; Other: Control Arm; Other: Exercise capacity VO2 maximum determination; Other: Exercise Challenge Sponsor: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 1, 2023 Category: Research Source Type: clinical trials